Tirzepatide (LY3298176)
Synthetic 39-amino-acid peptide engineered as a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Marketed by Eli Lilly as Mounjaro (for Type 2 diabetes) and Zepbound (for chronic weight management). Approved by US FDA, EMA, and Egyptian Drug Authority.
60-Second Scientific Briefing
Tirzepatide is an FDA-approved single synthetic peptide with dual agonist activity at glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. Approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), it produced up to 20.9% mean weight loss at 72 weeks in SURMOUNT-1.
What is Tirzepatide?
Pharmacological Classification & Molecular IdentityLinear 39-amino-acid synthetic peptide modified with a C20 fatty diacid moiety attached at Lys20 via a linker.
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingBiological pathway and target receptor binding mechanism.
Receptor Selectivity: Co-activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, insulin sensitivity in adipose tissue, and central satiety pathways.
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsFDA Approved for Type 2 Diabetes (Mounjaro NDA 215866) and Chronic Weight Management (Zepbound NDA 217806).
Tirzepatide has received regulatory approval for specific medical indications. Commercial distribution and medical usage require appropriate prescription and adherence to approved labeling.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesPhase 3 SURMOUNT program for obesity demonstrating mean 20.9% weight reduction at 72 weeks, and SURPASS program for glycemic control in type 2 diabetes.
Clinical Evidence
Phase 3 SURMOUNT program for obesity demonstrating mean 20.9% weight reduction at 72 weeks, and SURPASS program for glycemic control in type 2 diabetes.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesGastrointestinal adverse reactions (nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia). Boxed warning for thyroid C-cell tumors.
Long-term cardiovascular outcomes in obesity cohorts without diabetes (SURMOUNT-MMO study ongoing).
Dose Approval Status
Commercial Dosing Status and Policy DirectivesFDA-approved subcutaneous weekly doses: 2.5 mg initiation for 4 weeks, escalating by 2.5 mg every 4 weeks to maintenance doses of 5 mg, 10 mg, or 15 mg.
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Linear 39-amino-acid synthetic peptide modified with a C20 fatty diacid moiety attached at Lys20 via a linker.
- Targets & Selectivity: Co-activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, insulin sensitivity in adipose tissue, and central satiety pathways.
- Phase 3 SURMOUNT program for obesity demonstrating mean 20.9% weight reduction at 72 weeks, and SURPASS program for glycemic control in type 2 diabetes.
- Safety considerations: Gastrointestinal adverse reactions (nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia). Boxed warning for thyroid C-cell tumors.
? Unknown / Under Ongoing Investigation
- Long-term cardiovascular outcomes in obesity cohorts without diabetes (SURMOUNT-MMO study ongoing).
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysTirzepatide is classified as a Dual GIP and GLP-1 Receptor Agonist. Molecular structure: Linear 39-amino-acid synthetic peptide modified with a C20 fatty diacid moiety attached at Lys20 via a linker..
Pharmacological classification and molecular integrity are documented in verified regulatory and scientific literature.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
Tirzepatide exerts biological activity via Co-activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, insulin sensitivity in adipose tissue, and central satiety pathways..
Receptor binding affinity and selectivity dictate the physiological response observed in laboratory and clinical trials.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
Regulatory status: FDA Approved for Type 2 Diabetes (Mounjaro NDA 215866) and Chronic Weight Management (Zepbound NDA 217806).
Prescription use requires a verified medical diagnosis and adherence to approved labeling.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
Clinical evaluation status: Phase 3 SURMOUNT program for obesity demonstrating mean 20.9% weight reduction at 72 weeks, and SURPASS program for glycemic control in type 2 diabetes.
Clinical trial readouts and systematic analyses establish the boundary between demonstrated findings and experimental hypotheses.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
- Tirzepatide Once Weekly for the Treatment of Obesity (New England Journal of Medicine, 2022-07-21)
Reported safety profile: Gastrointestinal adverse reactions (nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia). Boxed warning for thyroid C-cell tumors.
Adverse reaction monitoring and contraindications are critical parameters in pharmacological risk-benefit evaluation.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
Key scientific uncertainties: Long-term cardiovascular outcomes in obesity cohorts without diabetes (SURMOUNT-MMO study ongoing).
Egypt Peptides enforces strict transparency regarding scientific limitations and gaps in longitudinal clinical data.
- Tirzepatide Once Weekly for the Treatment of Obesity (New England Journal of Medicine, 2022-07-21)
FDA-approved subcutaneous weekly doses: 2.5 mg initiation for 4 weeks, escalating by 2.5 mg every 4 weeks to maintenance doses of 5 mg, 10 mg, or 15 mg.
Under medical governance mandates, clinical study dosages represent strictly controlled experimental parameters and must never be interpreted as individual therapeutic advice.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
Storage status: Store refrigerated at 2°C to 8°C (36°F to 46°F). May be stored unrefrigerated up to 30°C (86°F) for up to 21 days in original carton.
Peptide integrity degrades rapidly when exposed to elevated temperatures, repeated freeze-thaw cycles, or direct UV light exposure.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
Athletic status depends on WADA category classification; peptide hormones, growth factor mimetics, and related substances are prohibited under WADA Section S2.
Athletes subject to drug testing face strict liability and multi-year competition bans upon detection of prohibited peptides or their metabolites.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
Egypt Peptides provides peer-reviewed scientific reference monographs for research documentation. We strictly prohibit individual medical consultations, reconstitution guides, stacking recipes, or off-label use instructions.
All scientific claims must link to verified authoritative sources (FDA, PubMed, ClinicalTrials.gov) with zero tolerance for ungrounded marketing claims.
- FDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2022-05-13)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and peer-reviewed studiesFDA Drugs@FDA Database: MOUNJARO / ZEPBOUND (Tirzepatide) Approval History and Prescribing Information ↗
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
Tirzepatide Once Weekly for the Treatment of Obesity ↗
https://www.nejm.org/doi/10.1056/NEJMoa2206038